DAWEX
17.3.2022 17:52:08 CET | Business Wire | Press release
With more than 80% of industrial data[1] remaining unused, the Data Act calls for the need of fundamental measures to regulate data circulation in order to make data more accessible for all. Granting consumers and companies the control over who accesses their data, for what purpose, is a pillar principle to future measures in order to unlock the richness of industrial data and build a regulated, fair European data economy. Dawex Data Exchange technology awards platform orchestrators the capability to keep control over the circulation of data through a secure, trusted data sharing and data exchange environment ensuring visibility of which data is being used, for which usage, under which terms.
In today’s economy where data has become a product with its own value, not limited to its usage, and the source of new revenue streams, Dawex technology allows organizations to create and gather new ecosystems around data exchange platforms that meet regulatory frameworks and addresses traceability and security challenges. Dawex is the leading technology company for data exchange , data marketplace and data hub , whose mission is to facilitate and accelerate secure data circulation between all economic stakeholders.
As the European Data Act stresses the critical importance of industrial data circulation in order to foster European data-driven innovation, Dawex technology has already demonstrated its operational and business value in more than 20 sectors such as agriculture, space, retail, agrifood, automotive, infrastructure, tourism, real estate and mobility by helping organizations in those industries address economical, social and environmental challenges.
The future Data Act is designed to harmonize rules on the fair access to and use of data generated in the EU across all economic sectors. The proposed measures encompass:
- Facilitating access to generated IoT data to boost data-driven innovative services development,
- Rebalancing SMEs’ negotiating power to prevent contractual misconducts in data exchange contracts,
- Allowing public sector bodies access to data held by companies in public emergencies situations,
- Defining new rules for data and cloud interoperability to simplify cloud and edge service providers switch,
- Safeguarding unlawful data access and transfer by non-EU governments.
Dawex Data Exchange solution provides all the means and capabilities for data providers, data users and data exchange service providers to implement the future Data Act principles by delivering the high level of flexibility, traceability, and control available to all parties involved in data exchange. Data products can be clearly defined, accessed, and exchanged under flexible and fully configurable licensing terms, free of charge or against compensation.
“The Data Act’s ambition is to ensure a fair and innovative European data economy by making data more available for reuse to stimulate data-driven innovation.” said Laurent Lafaye, co-CEO at Dawex. “Since its inception, Dawex has been committed to delivering cutting-edge data exchange technology to bring the perfect conditions for secure and compliant data sharing. Dawex Data Exchange solutions are already aligned to what the Data Act proposes.”
Available in white label, Dawex Data Exchange, Data Hub and Data Marketplace solutions are today the only solutions on the market to offer such easy, efficient and highly secure data exchange capabilities.
“The development of Data Exchange technology facilitates the circulation of data between all economic stakeholders, supporting the flexible deployment of data ecosystems and their interconnection.” said Fabrice Tocco, Dawex co-CEO. “The European Data Act is another critical milestone that confirms Dawex vision and its technological direction for data exchange, driving a strong data economy.”
About Dawex
Dawex is the leading technology company for data exchange , data marketplace and data hub . Dawex mission is to facilitate and accelerate secure data circulation between economic stakeholders, institutions and private organizations, contributing to the development of the data economy. Awarded Technology Pioneer by the World Economic Forum, Dawex is a member of Gaia-X and a co-founding member of the Data Exchange Association . Created in 2015, Dawex has offices in France and Canada, expanding business operations to Asia, North America and the Middle East.
[1] Source: European Commission
View source version on businesswire.com: https://www.businesswire.com/news/home/20220317005725/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom